The use of ALK kinase inhibitors have been shown to be promising in treatment of Non-Small-Cell Lung Cancer (NSCLC), Anaplastic Large Lymphoma (ALL) and other cancers with an ALK-driven component, and for these reasons novel small-molecule inhibitors suitable for clinical applications are in development or in early-phase trials [29–31]. The gene discussed is ALK; the disease is cancer.